Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a Phase 3 study titled ‘A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State.’ The study aims to assess the impact of dazodalibep on patient-reported symptoms and outcomes in individuals with moderate-to-severe Sjögren’s Syndrome, as well as its safety and tolerability.
The intervention being tested is dazodalibep, administered via intravenous infusion. It is designed to alleviate symptoms associated with Sjögren’s Syndrome, a chronic autoimmune condition.
This interventional study employs a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded. The primary purpose of the study is treatment.
The study began on April 8, 2024, with its primary completion and estimated completion dates yet to be disclosed. The latest update was submitted on August 6, 2025, indicating ongoing progress.
For investors, this study represents a significant development for Amgen, potentially enhancing its market position if successful. The outcome could influence stock performance and investor sentiment, especially given the competitive landscape in autoimmune disease treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.